MedTrace Logo

KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)

NCT02777567 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 315

Last updated 2020-09-10

No results posted yet for this study

Summary

The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study drug") in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or after EGFR tyrosine kinase receptor (TKI) therapy.

Conditions

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-29
Primary Completion
2020-03-19
Completion
2020-03-19

Countries

  • South Korea

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02777567 on ClinicalTrials.gov